Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05894889 | Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC | active not recruiting | Phase 2 | 70 | Peking UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06951464 | A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC | recruiting | Phase 2 | 40 | Sichuan UniversityOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT04136535 |
| Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC(PCA) |
| recruiting |
| Phase 2 |
| 105 |
| Fudan UniversityOTHER |
| 1 |
| Jul 22, 2025 |
| clinicaltrials |
| NCT06951399 | Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer | not yet recruiting | Phase 2 | 30 | Rabin Medical CenterOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07076693 | Standard-of-care Systemic Therapy With or Without Local Therapy in Patients With Oligoprogressive Non-Small Cell Lung Cancer(NSCLC） | active not recruiting | Phase 2 / Phase 3 | 97 | Shanghai Chest HospitalOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT07076914 | Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy(PPI-PROTECT) | not yet recruiting | Phase 2 | 58 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT06709859 | Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC | recruiting | Phase 2 | 30 | Shandong Public Health Clinical CenterOTHER_GOV | 1 | Jul 17, 2025 | clinicaltrials |
| NCT06962865 | A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC | recruiting | Phase 2 | 80 | RemeGen Co., Ltd.INDUSTRY | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06617936 | Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. | recruiting | Phase 2 | 36 | Hua ZhangOTHER_GOV | 1 | Jul 15, 2025 | clinicaltrials |
| NCT06379087 | Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC | recruiting | Phase 2 | 20 | Ji YonglingOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT07037680 | Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT | recruiting | Phase 2 | 44 | JIANYANG WANGOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT05286294 | Microbiota Transplant to Cancer Patients Who Have Failed Immunotherapy Using Faeces From Clinical Responders(MITRIC) | active not recruiting | Phase 2 | 20 | Oslo University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT07043907 | PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC | not yet recruiting | Phase 2 | 115 | Shenzhen Celconta Life Science Co., Ltd.INDUSTRY | 0 | Jul 1, 2025 | clinicaltrials |
| NCT06977828 | A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC | not yet recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors(SPARTA) | recruiting | Phase 2 | 497 | Apollomics Inc.INDUSTRY | 11 | Jun 27, 2025 | clinicaltrials |
| NCT07038460 | A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC(NEO-LISI) | not yet recruiting | Phase 2 | 134 | Wen-zhao ZHONGOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07035392 | Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC | not yet recruiting | Phase 2 | 32 | Zhangzhou Municipal HospitalOTHER | 0 | Jun 25, 2025 | clinicaltrials |
| NCT07034326 | Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 405 | Kong FanmingOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07034391 | A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status | recruiting | Phase 2 | 40 | China Medical University, ChinaOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07031154 | A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer | not yet recruiting | Phase 2 | 43 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT06276283 | DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) | recruiting | Phase 2 | 60 | Dizal PharmaceuticalsINDUSTRY | 1 | Jun 19, 2025 | clinicaltrials |
| NCT06205927 | Randomized Study of Carbon Ion Boost in Hypoxic Lesions for Locally Advanced Non-small Cell Lung Cancer | recruiting | Phase 2 | 77 | Jian ChenOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT05180799 | A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 320 | BioAtla, Inc.INDUSTRY | 2 | Jun 15, 2025 | clinicaltrials |
| NCT04533451 | Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 101 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT05613452 | Carbon Ion Therapy for Peripheral Non-small Cell Lung Cancer | recruiting | Phase 2 | 43 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT06311981 | Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients | recruiting | Phase 2 | 29 | Jian ChenOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT04027647 | Phase 2 Study of Dacomitinib in NSCLC | active not recruiting | Phase 2 | 118 | National Cancer Centre, SingaporeOTHER | 5 | Jun 12, 2025 | clinicaltrials |
| NCT05319574 | SBRT Followed by Neoadjuvant Immunochemotherapy in Resectable Stage II to III Non-small Cell Lung Cancer(SACTION01) | active not recruiting | Phase 2 | 46 | Sun Yat-sen UniversityOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05765877 | Neoadjuvant WX-0593 in Resectable ALK-positive or ROS1-positive Non-small Cell Lung Cancer | recruiting | Phase 2 | 26 | Pingping SongOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT04946968 | Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers | active not recruiting | Phase 2 | 24 | National Cancer Centre, SingaporeOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT07014215 | PD-1 Combined With Bevacizumab and PCSK-9 Inhibitor in Patients With Advanced NSCLC Who Have Progressed After Anti- PD- 1/L1 Therapy | not yet recruiting | Phase 2 | 52 | Anhui Provincial Cancer HospitalOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT06929936 | Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC(PROTECT-1) | recruiting | Phase 2 | 33 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT07009925 | Phase II Study of Platinum (Cisplatin/Carboplatin)and Polymeric Micelles Paclitaxel(Pm-Pac) With Ivonescimab in First Line Metastatic Squamous NSCLC. | not yet recruiting | Phase 2 | 38 | Jiangsu Cancer Institute & HospitalOTHER | 0 | Jun 8, 2025 | clinicaltrials |
| NCT06998719 | Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC(ACCESS) | not yet recruiting | Phase 2 | 80 | Bi NanOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT03970746 | Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC | active not recruiting | Phase 1 / Phase 2 | 73 | PDC*line Pharma SASINDUSTRY | 5 | May 29, 2025 | clinicaltrials |
| NCT04043195 | Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC(NSCLC) | active not recruiting | Phase 1 / Phase 2 | 30 | Hatim HusainOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06977074 | PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC(PROPHET) | recruiting | Phase 2 | 83 | Sun Yat-sen UniversityOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06343064 | Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI(KYLIN-1) | recruiting | Phase 1 / Phase 2 | 156 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT06574347 | Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.(KYLIN-2) | recruiting | Phase 2 | 120 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT05955391 | TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 2 | 164 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT06659042 | Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer | recruiting | Phase 2 | 32 | Shanghai Chest HospitalOTHER | 1 | May 18, 2025 | clinicaltrials |
| NCT06971406 | High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis(FLAME-1) | not yet recruiting | Phase 2 | 100 | Qiming WangOTHER_GOV | 0 | May 14, 2025 | clinicaltrials |
| NCT05631249 | Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C(CODEBREAK-IGR) | recruiting | Phase 2 | 40 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT06962189 | The Efficacy and Safety of Sintilimab Plus Chemotherapy in Surgical Conversion for Patients With Unresectable Stage IIIB-IIIC NSCLC: A Prospective, Single-Arm, Phase II Study | not yet recruiting | Phase 2 | 39 | Zhejiang UniversityOTHER | 0 | May 8, 2025 | clinicaltrials |
| NCT06498986 | A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | recruiting | Phase 2 | 40 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 7, 2025 | clinicaltrials |
| NCT02983578 | Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer | active not recruiting | Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06401824 | Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases | recruiting | Phase 2 | 25 | Maastricht University Medical CenterOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT05994131 | IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC | recruiting | Phase 1 / Phase 2 | 110 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 23, 2025source: clinicaltrials